Peptide Comparison
MazdutidevsTirzepatide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
At a Glance
Quick
comparison
Dose Range
Mazdutide
3 mg–9 mg mg
Tirzepatide
2.5–15 mg
Frequency
Mazdutide
Once daily
Tirzepatide
Once weekly
Administration
Mazdutide
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle Length
Mazdutide
Ongoing/indefinite
Tirzepatide
Ongoing/indefinite
Onset Speed
Mazdutide
Moderate (1-2 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence Level
Mazdutide
Strong human trials (Phase 3 or FDA approved)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Weight Loss
Blood Sugar Control
Metabolic Health
Appetite Control
Technical Data
Compound
specifications
Mazdutide
Molecular Formula
C210H322N46O67
Molecular Weight
4563.1 Da
Half-Life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
CAS Number
2259884-03-0
Tirzepatide
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Half-Life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS Number
2023788-19-2
Protocols
Dosing
tiers
Mazdutide
Tirzepatide
Applications
Best
suited for
Mazdutide
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.
Safety Profile
Side
effects
Mazdutide
Common
- Nausea
- Diarrhea
- Decreased Appetite
Uncommon
- Vomiting
- Injection Site Reactions
Serious
- Acute Pancreatitis
- Acute Cholecystitis and Biliary Disease
- Severe Nausea and Gastrointestinal Intolerance
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research Status
Safety
& evidence
Mazdutide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Research compound
Safety Overview
Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects. Nausea/vomiting occur in 40-50% of subjects at higher doses; weight loss averaging 12-18% observed. Pancreatitis risk monitoring required; calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma or MEN2 syndrome
- xKnown hypersensitivity to mazdutide or any formulation excipients
- xHistory of severe pancreatitis
- xSevere renal impairment (eGFR <15 mL/min) without clinical data
Tirzepatide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
- xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
- xCurrent or recent pancreatitis
- xPregnancy or planning to become pregnant
Decision Guide
Which is
right for you?
Choose Mazdutide if...
- Individuals seeking substantial weight loss exceeding 15% body weight
- Adults with type 2 diabetes requiring superior glycemic management
- Patients with obesity-related metabolic comorbidities
- Those seeking dual-mechanism metabolic therapy
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement